Pham Quang X sold $15K of CVKD
Pham Quang X (CEO and Chairman) sold 2,989 shares of Cadrenal Therapeutics, Inc. (CVKD) at $4.93 on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale by the CEO/Chairman can influence short-term sentiment, but 10b5-1 pre-arranged plans are generally less informative about near-term outlook.
Market read
Traders may monitor for follow-on insider activity, but this single 10b5-1 sale is unlikely to drive a fundamental repricing by itself.
What to watch
The filing does not indicate whether other insiders bought/sold around the same time, nor does it provide context on total insider ownership changes beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
CEO/Chairman and 10% owner Pham Quang X sold 2,989 shares in an open-market transaction disclosed via SEC Form 4.
Likely limited immediate impact; any reaction may be short-lived unless accompanied by other catalysts.
Form 4 reports the sale price/size and confirms a pre-arranged 10b5-1 plan, which typically dampens directional inference.
Market effects
Minimal; this is company-specific insider activity with no stated operational or regulatory change.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the SEC Form 4 insider transaction disclosure (CVKD).
- insiderPham Quang X
CEO and Chairman; 10% owner who sold shares under a pre-arranged 10b5-1 plan.
